April 11, 2024Journal of Clinical MedicineOpen Access

Examining Lurasidone Efficacy in Patients with Schizophrenia Spectrum Illness and Concurrent Alcohol and Substance Use Disorder: A Prospective, Multicentric, Real-World Investigation

View Full Paper

Ask AI

Bookmark

Authors

CCClara CavallottoUniversity of Chieti-Pescara SCStefania ChiappiniUniversity of Hertfordshire AMAlessio MoscaUniversity of Chieti-Pescara

Discussion

Member takes

Implication

Prospective multicentric study demonstrates reduced psychopathology and craving in schizophrenia with substance use disorders, highlighting therapeutic utility for dual diagnoses.

Key Points

Lurasidone significantly reduces psychopathology and craving in schizophrenia spectrum disorder patients presenting with comorbid substance use disorder.
Total PANSS scores decreased significantly (Z = 2.574, p = 0.011), while substance craving and aggression scales demonstrated marked improvements.
Prospective cohort assessment across multiple clinical centers demonstrated high tolerability, supporting atypical antipsychotic use in dual disorders.

Cite This Study

Cavallotto et al. (2024) studied this question.

synapsesocial.com/papers/68e6f83cb6db6435876722e4 https://doi.org/10.3390/jcm13082206

View Full Paper

Ask AI

Bookmark

Implication

Prospective multicentric study demonstrates reduced psychopathology and craving in schizophrenia with substance use disorders, highlighting therapeutic utility for dual diagnoses.

Examining Lurasidone Efficacy in Patients with Schizophrenia Spectrum Illness and Concurrent Alcohol and Substance Use Disorder: A Prospective, Multicentric, Real-World Investigation

Discussion

Member takes

Implication

Key Points

Cite This Study

Examining Lurasidone Efficacy in Patients with Schizophrenia Spectrum Illness and Concurrent Alcohol and Substance Use Disorder: A Prospective, Multicentric, Real-World Investigation

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider